Location
Suwanee, GA
Start Date
7-5-2024 1:00 PM
End Date
7-5-2024 4:00 PM
Description
INTRODUCTION: According to the World Cancer Research Fund International (WCRFI), breast cancer (12.5%) has now topped lung cancer (12.2%) as the most prevalent form of cancer in the world (WCRFI, 2022). While therapeutic advances continue to be made, the current treatment of cancer is widely associated with severe side effects from classic therapies such as radiation and chemotherapy. Over the last two decades, studies have examined breast cancer vaccines in pre-clinical and clinical settings. Here, we present an in-depth review of current mRNA-based cancer vaccine literature to assess the prevalence of this technology in this field of medicine. This includes the evaluation of mRNA itself, current delivery systems for mRNA, and previous as well as current clinical trials with mRNA-based vaccines. This information can aid in the evaluation of potential use for this technology, for breast cancer prevention specifically. Although there are current mRNA-based cancer vaccines that have either completed clinical trials or are in the process of doing so, this technology is just recently being tested to increase prevention strategies for breast cancer in particular. However, current research continues to gain popularity regarding this shortcoming, and is a hopeful area of current scientific investigation.
OBJECTIVES: To evaluate current research on mRNA-based cancer vaccinations, as well as those that have been reported in clinical trial testing. This information can then be applied to the current lack of this technology regarding breast cancer.
METHODS: An in-depth review of current mRNA-based cancer vaccine literature will be conducted to assess the prevalence of this technology in this field of medicine. This includes the evaluation of mRNA itself, current delivery systems for mRNA, and previous as well as current clinical trials with mRNA-based vaccines. This information can aid in the evaluation of potential use for this technology, for breast cancer prevention specifically.
RESULTS: Current research shows evidence of mRNA-based cancer vaccinations that have been evaluated throughout various clinical trial phases. mRNA has been used successfully to mitigate infectious disease - a prime example being the COVID-19 vaccine. This technology has proven to be reliable and further research might suggest this could also be applied to the prevention of breast cancer.
DISCUSSION: Although there are current mRNA-based cancer vaccines that have either completed clinical trials or are in the process of doing so, this technology is just recently being tested to increase prevention strategies for breast cancer in particular. However, current research continues to gain popularity regarding this shortcoming, and is a hopeful area of current scientific investigation.
Embargo Period
6-24-2024
Included in
A review of current mRNA-based cancer vaccinations with special consideration for future breast cancer prevention strategies
Suwanee, GA
INTRODUCTION: According to the World Cancer Research Fund International (WCRFI), breast cancer (12.5%) has now topped lung cancer (12.2%) as the most prevalent form of cancer in the world (WCRFI, 2022). While therapeutic advances continue to be made, the current treatment of cancer is widely associated with severe side effects from classic therapies such as radiation and chemotherapy. Over the last two decades, studies have examined breast cancer vaccines in pre-clinical and clinical settings. Here, we present an in-depth review of current mRNA-based cancer vaccine literature to assess the prevalence of this technology in this field of medicine. This includes the evaluation of mRNA itself, current delivery systems for mRNA, and previous as well as current clinical trials with mRNA-based vaccines. This information can aid in the evaluation of potential use for this technology, for breast cancer prevention specifically. Although there are current mRNA-based cancer vaccines that have either completed clinical trials or are in the process of doing so, this technology is just recently being tested to increase prevention strategies for breast cancer in particular. However, current research continues to gain popularity regarding this shortcoming, and is a hopeful area of current scientific investigation.
OBJECTIVES: To evaluate current research on mRNA-based cancer vaccinations, as well as those that have been reported in clinical trial testing. This information can then be applied to the current lack of this technology regarding breast cancer.
METHODS: An in-depth review of current mRNA-based cancer vaccine literature will be conducted to assess the prevalence of this technology in this field of medicine. This includes the evaluation of mRNA itself, current delivery systems for mRNA, and previous as well as current clinical trials with mRNA-based vaccines. This information can aid in the evaluation of potential use for this technology, for breast cancer prevention specifically.
RESULTS: Current research shows evidence of mRNA-based cancer vaccinations that have been evaluated throughout various clinical trial phases. mRNA has been used successfully to mitigate infectious disease - a prime example being the COVID-19 vaccine. This technology has proven to be reliable and further research might suggest this could also be applied to the prevention of breast cancer.
DISCUSSION: Although there are current mRNA-based cancer vaccines that have either completed clinical trials or are in the process of doing so, this technology is just recently being tested to increase prevention strategies for breast cancer in particular. However, current research continues to gain popularity regarding this shortcoming, and is a hopeful area of current scientific investigation.
Comments
Presented by Alexa Cornwell.